var data={"title":"Imipramine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Imipramine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6360?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=imipramine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Imipramine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=imipramine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Imipramine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708918\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Suicidality and antidepressant drugs:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Antidepressants increased the risk compared with placebo of suicidal thinking and behavior (suicidality) in short-term studies in children, adolescents, and young adults with major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of imipramine or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared with placebo in adults older than 24 years; there was a reduction in risk with antidepressants compared with placebo in adults 65 years and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the health care provider. Imipramine is not approved for use in pediatric patients except for patients with nocturnal enuresis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182136\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tofranil;</li>\n      <li>Tofranil-PM [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182137\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Impril</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182180\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidepressant, Tricyclic (Tertiary Amine)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182141\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Depression: </b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Outpatients</i>: Initial: 75 mg/day; may increase gradually to 150 mg/day. May be given in divided doses or as a single bedtime dose; maintenance 50 to 150 mg/day; maximum: 200 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Inpatients</i>: Initial: 100 to 150 mg/day; may increase gradually to 200 mg/day; if no response after 2 weeks, may further increase to 250 to 300 mg/day. May be given in divided doses or as a single bedtime dose; maximum: 300 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bulimia nervosa (off-label use):</b> Oral: Initial: 50 mg at bedtime; increase gradually based on response and tolerability up to 300 mg at bedtime (Agras 1987; Mitchell 1990; Pope 1983).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neuropathic pain (off-label use):</b> Oral: <b>Note:</b> Not the preferred TCA (Bril 2011; Dworkin 2007). Initial: 50 mg once daily or in divided doses twice daily; increase gradually up to 150 mg daily (Kvinesdal 1984; Sindrup 2003) or to a dosage sufficient to achieve an imipramine plus desipramine plasma concentration of 113-170 ng/mL (SI: 400-600 nmol/L) (Sindrup 1989; Sindrup 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Panic disorder (off-label use):</b> Oral: Initial: 10 mg/day; increase gradually over 3 to 5 weeks to a target dose of 100 to 300 mg/day; mean doses in studies ranged from 155 to 239 mg/day (APA [Stein 2009]; Barlow 2000; Cross-National Collaborative Panic Study 1992; WFSBP [Bandelow 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Post-traumatic stress disorder (PTSD) (off-label use):</b> Oral: Initial: 50 mg once daily; increase gradually to 200-300 mg once daily to achieve blood levels in the therapeutic range (&gt;150 ng/mL) (Frank 1988; Kosten 1991)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Discontinuation of therapy:</b> Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporting ideal taper rates is limited. APA and NICE guidelines suggest tapering therapy over at least several weeks with consideration to the half-life of the antidepressant; antidepressants with a shorter half-life may need to be tapered more conservatively. In addition for long-term treated patients, WFSBP guidelines recommend tapering over 4 to 6 months. If intolerable withdrawal symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate (APA 2010; Bauer 2002; Haddod 2001; NCCMH 2010; Schatzberg 2006; Shelton 2001; Warner 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>MAO inhibitor recommendations:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Switching to or from an MAO inhibitor intended to treat psychiatric disorders:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of imipramine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Allow 14 days to elapse between discontinuing imipramine and initiation of an MAO inhibitor intended to treat psychiatric disorders.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182158\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=imipramine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Imipramine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Manufacturer labeling warns against use of doses &gt;2.5 mg/kg/<b>day</b> in pediatric patients; ECG changes (of unknown significance) have been reported in pediatric patients who received twice this amount.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Depression:</b> Adolescents: Oral: Initial: 30 to 40 mg/day; increase gradually; maximum: 100 mg/day in single or divided doses. <b>Note:</b> Controlled clinical trials have not shown tricyclic antidepressants to be superior to placebo for the treatment of depression in children and adolescents; not recommended as first-line medication; may be beneficial for patient with comorbid conditions (ADHD, enuresis) (Birmaher 2007; Dopheide 2006; Wagner 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Enuresis: </b> <i>Imipramine hydrochloride:</i> Children &ge;6 years and Adolescents: Oral: Initial: 10 to 25 mg 1 hour before bedtime (Kliegman 2007), if inadequate response still seen after 1 week of therapy, increase by 25 mg daily; dose should not exceed 2.5 mg/kg/day or 50 mg at bedtime if 6 to 12 years or 75 mg at bedtime if &ge;12 years.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Attention-deficit/hyperactivity disorder (off-label use):</b> Children &ge;6 years and Adolescents: Oral: Initial: 1 mg/kg/day; titrate as needed; maximum daily dose: 4 mg/kg/<b>day</b> or 200 mg <b>daily</b>; for doses &gt;2 mg/kg/day, monitor serum concentrations (target: &le;200 ng/mL) (Himpel 2005; Pliszka 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Discontinuation of therapy:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>MAO inhibitor recommendations:</b> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182142\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Depression:</b> Initial: 30 to 40 mg at bedtime; may increase every 3 days for inpatients and weekly for outpatients if tolerated to a recommended maximum of 100 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Discontinuation of therapy:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>MAO inhibitor recommendations:</b> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897618\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897619\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182116\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as pamoate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tofranil-PM: 75 mg [DSC], 100 mg [DSC], 125 mg [DSC], 150 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 75 mg, 100 mg, 125 mg, 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tofranil: 10 mg, 25 mg, 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 25 mg, 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182101\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23797397\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral, as hydrochloride: 75 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874618\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Antidepressant medications: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/ucm100211.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+tzXKjYwuZYZylkP+kRnn+doVL8tsWmc2MIZh/g1QzjAAGI4EzKpddG0l/j8K0NuhbXvXOgWPXisGp8KlvcP9h&amp;TOPIC_ID=8554\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/ucm100211.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Tofranil-PM: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM326090.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5W/l5FJRmg3267IE6YYHFsZQ==&amp;TOPIC_ID=8554\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM326090.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182120\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Childhood enuresis (imipramine hydrochloride only):</b> As temporary adjunctive therapy in reducing enuresis in children &ge;6 years of age, after possible organic causes have been excluded by appropriate tests</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Depression:</b> Treatment of depression</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474698\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Attention-deficit/hyperactivity disorder (ADHD); Bulimia nervosa; Neuropathic pain; Panic disorder; Post-traumatic stress disorder (PTSD)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182188\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Imipramine may be confused with amitriptyline, desipramine, Norpramin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Imipramine (alone or in combination) is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its strong anticholinergic properties and potential for sedation and orthostatic hypotension. Because of their association with falls and fractures, tricyclic antidepressants (TCAs) are to be avoided in patients 65 years and older with a history of falls or fractures. In addition, use TCAs with caution due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Imipramine (alone or in combination) is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182108\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Reported for tricyclic antidepressants in general. Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Cardiac arrhythmia, cardiac failure, cerebrovascular accident, ECG changes, heart block, hypertension, myocardial infarction, orthostatic hypotension, palpitations, tachycardia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Agitation, anxiety, ataxia, confusion, delusions, disorientation, dizziness, drowsiness, EEG pattern changes, extrapyramidal reaction, falling, fatigue, hallucination, headache, hypomania, insomnia, nightmares, numbness, paresthesia, peripheral neuropathy, psychosis, restlessness, seizure, taste disorder, tingling sensation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Alopecia, diaphoresis, pruritus, skin photosensitivity, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Decreased libido, decreased serum glucose, galactorrhea, gynecomastia, increased libido, increased serum glucose, SIADH, weight gain, weight loss </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal cramps, anorexia, constipation, diarrhea, epigastric distress, intestinal obstruction, melanoglossia, nausea, stomatitis, sublingual adenitis, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Breast hypertrophy, impotence, testicular swelling, urinary hesitancy, urinary retention, urinary tract dilation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Agranulocytosis, eosinophilia, petechia, purpura, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Cholestatic jaundice, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Hypersensitivity (eg, drug fever, edema)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Tremor, weakness </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Accommodation disturbance, angle-closure glaucoma, blurred vision, mydriasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Tinnitus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182123\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to imipramine (cross-reactivity with other dibenzodiazepines may occur) or any component of the formulation; acute recovery period after a myocardial infarction (MI); use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either imipramine or the MAO inhibitor); initiation in patients receiving linezolid or methylene blue IV.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for tricyclic antidepressants is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182105\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Major psychiatric warnings:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal thinking/behavior: <b>[US Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18 to 24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;</b> consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1 to 2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient's family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription. <b>Imipramine is FDA approved for the treatment of nocturnal enuresis in children &ge;6 years of age.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, increased intraocular pressure, angle-closure glaucoma, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. The degree of anticholinergic blockade produced by this agent is high relative to other antidepressants.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving). The degree of sedation is high relative to other antidepressants.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fractures: Bone fractures have been associated with antidepressant treatment. Consider the possibility of a fragility fracture if an antidepressant-treated patient presents with unexplained bone pain, point tenderness, swelling, or bruising (Rabenda 2013; Rizzoli 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: TCAs may rarely cause bone marrow suppression; monitor for any signs of infection and obtain CBC if symptoms (eg, fever, sore throat) are evident. Discontinue imipramine if there is evidence of pathological neutrophil depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orthostatic hypotension: May cause orthostatic hypotension (risk is very high relative to other antidepressants); use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitization: Has been associated with photosensitization; avoid excessive exposure to sunlight.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John's wort, tryptophan) or agents that impair metabolism of serotonin (eg, MAO inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Alcohol use disorder: Pharmacokinetics of imipramine may be altered in patients with chronic alcohol use disorder; increased clearance and a decreased elimination half-life have been reported (Sallee 1990).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities); the risk of conduction abnormalities with this agent is high relative to other antidepressants. In a scientific statement from the American Heart Association, imipramine has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]). Baseline and periodic assessment of EKG is recommended with use of higher dosages, and should also be considered in elderly patients and/or patients with preexisting cardiovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose regulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder. <b>Imipramine is not FDA approved for the treatment of bipolar depression. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: May cause mild pupillary dilation which in susceptible individuals can lead to an episode of narrow-angle glaucoma. Consider evaluating patients who have not had an iridectomy for narrow-angle glaucoma risk factors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Children: A dose of 2.5 mg/kg/day of imipramine hydrochloride should not be exceeded in childhood. ECG changes of unknown significance have been reported in pediatric patients with doses twice this amount.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Lower doses may be required in geriatric patients due to pharmacokinetic changes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Smokers: Imipramine levels may be lower in patients who smoke (Sallee 1990).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Dosage form specific issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tartrazine: Some formulations may contain tartrazine (FD&amp;C Yellow No. 5) which may cause allergic-type reactions (including bronchial asthma) in susceptible individuals, particularly those who also have aspirin sensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation syndrome: Abrupt discontinuation or interruption of antidepressant therapy has been associated with a discontinuation syndrome. Symptoms arising may vary with antidepressant however commonly include nausea, vomiting, diarrhea, headaches, light-headedness, dizziness, diminished appetite, sweating, chills, tremors, paresthesias, fatigue, somnolence, and sleep disturbances (eg, vivid dreams, insomnia). Less common symptoms include electric shock-like sensations, cardiac arrhythmias (more common with tricyclic antidepressants), myalgias, parkinsonism, arthralgias, and balance difficulties. Psychological symptoms may also emerge such as agitation, anxiety, akathisia, panic attacks, irritability, aggressiveness, worsening of mood, dysphoria, mood lability, hyperactivity, mania/hypomania, depersonalization, decreased concentration, slowed thinking, confusion, and memory or concentration difficulties. Greater risks for developing a discontinuation syndrome have been associated with antidepressants with shorter half-lives, longer durations of treatment, and abrupt discontinuation. For antidepressants of short or intermediate half-lives, symptoms may emerge within 2 to 5 days after treatment discontinuation and last 7 to 14 days (APA 2010; Fava 2006; Haddod 2001; Shelton 2001; Warner 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgery: Recommended by the manufacturer to discontinue prior to elective surgery; risks exist for drug interactions with anesthesia and for cardiac arrhythmias. However, definitive drug interactions have not been widely reported in the literature and continuation of tricyclic antidepressants is generally recommended as long as precautions are taken to reduce the significance of any adverse events that may occur. Norepinephrine should be considered the vasopressor of choice for TCA-related hypotension (Pass 2004). Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182174\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (major), CYP2D6 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2E1 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182110\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8554&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).  Management: Avoid, if possible, the use of direct-acting alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the vasopressor effect of Alpha1-Agonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists. <b> Exceptions: </b>Apraclonidine; Brimonidine (Ophthalmic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha2-Agonists (Ophthalmic): Tricyclic Antidepressants may diminish the therapeutic effect of Alpha2-Agonists (Ophthalmic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amezinium: May enhance the adverse/toxic effect of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Specifically, both drugs have the potential to decrease the seizure threshold, possibly increasing the risk for seizures. Tricyclic Antidepressants may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aspirin: Tricyclic Antidepressants (Tertiary Amine) may enhance the antiplatelet effect of Aspirin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May increase the metabolism of Tricyclic Antidepressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the adverse/toxic effect of Tricyclic Antidepressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May decrease the metabolism of Tricyclic Antidepressants. Management: Seek alternatives when possible. Monitor patients receiving these combinations closely for increased serum concentrations (when testing is available) and toxic effects of the tricyclic antidepressant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants. Management: Seek alternatives when possible. If these combinations are used, monitor closely for increased effects/toxicity and/or elevated serum concentrations (when testing is available) of the tricyclic antidepressant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Citalopram: Tricyclic Antidepressants may enhance the adverse/toxic effect of Citalopram. Tricyclic Antidepressants may increase the serum concentration of Citalopram. Citalopram may increase the serum concentration of Tricyclic Antidepressants.  Management: Consider alternatives to this combination when possible.  Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with citalopram.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C19 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: Tricyclic Antidepressants may enhance the arrhythmogenic effect of Dronedarone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. DULoxetine may decrease the metabolism of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Conversely, concentrations of active metabolites may be increased for those drugs activated by CYP2C19. Management: Concurrent use of enzalutamide with CYP2C19 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP2C19 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Escitalopram: Tricyclic Antidepressants may enhance the adverse/toxic effect of Escitalopram. Escitalopram may increase the serum concentration of Tricyclic Antidepressants.  Management: Consider alternatives to this combination when possible.  Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with escitalopram.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FLUoxetine: May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants. Management: Consider alternatives to this combination when possible.  Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with fluoxetine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May enhance the adverse/toxic effect of Tricyclic Antidepressants. FluvoxaMINE may increase the serum concentration of Tricyclic Antidepressants. Management: Consider alternatives to this combination when possible.  Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with fluvoxamine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: Tricyclic Antidepressants may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants. Management: This combination should be undertaken with great caution.  When combined treatment is clinically indicated, monitor closely for signs of serotonin toxicity/serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melatonin: May enhance the adverse/toxic effect of Imipramine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: May enhance the adverse/toxic effect of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.  While methylene blue and linezolid are expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to monographs specific to those agents for details.<b> Exceptions: </b>Linezolid; Methylene Blue; Tedizolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: Tricyclic Antidepressants may enhance the hypotensive effect of Nicorandil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Tricyclic Antidepressants (Tertiary Amine) may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Tricyclic Antidepressants (Tertiary Amine) may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PARoxetine: May enhance the adverse/toxic effect of Tricyclic Antidepressants. PARoxetine may increase the serum concentration of Tricyclic Antidepressants. Management: Consider alternatives to this combination when possible.  Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with paroxetine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: Tricyclic Antidepressants may diminish the therapeutic effect of Pitolisant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sertraline: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Sertraline may increase the serum concentration of Tricyclic Antidepressants. Management: Consider alternatives to this combination when possible.  Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with sertraline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terbinafine (Systemic): May increase the serum concentration of Imipramine. Management: Monitor for increased effects/toxicity of imipramine during concomitant administration with terbinafine. Reduced dosages of imipramine may be needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: May enhance the arrhythmogenic effect of Tricyclic Antidepressants. Thyroid Products may enhance the stimulatory effect of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May increase the serum concentration of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10949669\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies are inconclusive. Congenital abnormalities have been reported in humans; however, a causal relationship has not been established. Tricyclic antidepressants may be associated with irritability, jitteriness, and convulsions (rare) in the neonate (Yonkers 2009). Due to pregnancy-induced physiologic changes, women who are pregnant may require dose adjustments late in pregnancy to achieve euthymia (Altshuler 1996). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The ACOG recommends that therapy for depression during pregnancy be individualized; treatment should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician (ACOG 2008). According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery (APA 2010). Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy (Yonkers 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnant women exposed to antidepressants during pregnancy are encouraged to enroll in the National Pregnancy Registry for Antidepressants (NPRAD). Women 18 to 45 years of age or their health care providers may contact the registry by calling 844-405-6185. Enrollment should be done as early in pregnancy as possible.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10949670\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Imipramine and its active metabolite (desipramine) are present in breast milk (Sovner 1979). Concentrations of imipramine may be similar to those in the maternal plasma. Based on information from five mother/infant pairs, following maternal use of imipramine 75 to 200 mg/day, the estimated exposure to the breastfeeding infant would be 0.1% to 7.5% of the weight-adjusted maternal dose. Although adverse events were not reported, infants should be monitored for signs of adverse events (Fortinguerra 2009). Imipramine can also be detected in the urine of nursing infants (Yoshida 1997). Breastfeeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182113\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\"> CBC, ECG (baseline and with dose increases) in older adults, with high doses, and/or in patients with pre-existing cardiovascular disease; monitor blood pressure and pulse rate prior to and during initial therapy; evaluate mental status, suicide ideation (especially at the beginning of therapy or when doses are increased or decreased); anxiety, social functioning, panic attacks; signs/symptoms of serotonin syndrome; blood glucose; weight and BMI; blood levels are useful for therapeutic monitoring (APA 2010; Perrin 2008; Pliszka 2007; Vetter 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182117\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Therapeutic: Antidepressant effect: Imipramine and desipramine: 150 to 250 ng/mL (SI: 530 to 890 nmol/L); serum levels &gt;250 ng/mL (SI: 890 nmol/L) are associated with increased side effects without increase in antidepressant efficacy (Boyer 1984; Orsulak 1979; Task Force on the Use of Laboratory Tests in Psychiatry 1985).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182104\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Traditionally believed to increase the synaptic concentration of serotonin and/or norepinephrine in the central nervous system by inhibition of their reuptake by the presynaptic neuronal membrane. However, additional receptor effects have been found including desensitization of adenyl cyclase, down regulation of beta-adrenergic receptors, and down regulation of serotonin receptors.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182122\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Depression: Individual responses vary, however 4 to 8 weeks of treatment is needed before determining if a patient is partially or nonresponsive (APA 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Well absorbed; not affected by food (Sallee 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Children: 14.5 L/kg; Adults: ~10 to 20 L/kg (Sallee 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 60% to 96%; primarily to alpha1 acid glycoprotein and lipoproteins; to a lesser extent albumin (Sallee 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic, primarily via CYP2D6 to desipramine (active) and other metabolites; significant first-pass effect (Sallee 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 22% to 77% (Sallee 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 8 to 21 hours (Sallee 1990); Mean: Children: 11 hours; Adults: 16 to 17 hours; Desipramine (active metabolite): 22 to 28 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: 2 to 6 hours (Sallee 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (as metabolites; &lt;5% unchanged) (Sallee 1990)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182125\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Imipramine Pamoate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (30): $505.73</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $505.73</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (30): $505.73</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (30): $505.73</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Imipramine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $42.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $71.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $121.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Tofranil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $662.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $698.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $735.84</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182126\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Antidep (IN);</li>\n      <li>Bonil (UY);</li>\n      <li>Celamine (TH);</li>\n      <li>Chrytemin (JP);</li>\n      <li>Depram (BD);</li>\n      <li>Depramina (BR);</li>\n      <li>Depsol (IN);</li>\n      <li>Depsonil (IN);</li>\n      <li>Ethipramine (ZA);</li>\n      <li>Eupramin (HR);</li>\n      <li>Feinalmin (JP);</li>\n      <li>Fronil (TW);</li>\n      <li>Imidol (JP);</li>\n      <li>Imilanyle (JP);</li>\n      <li>Imimine (TW);</li>\n      <li>Imine (TW);</li>\n      <li>Imiprex (QA);</li>\n      <li>Melipramin (CZ, HN, HU, SK, UA);</li>\n      <li>Meripramin (JP);</li>\n      <li>Pinor (BD);</li>\n      <li>Pramin (BD);</li>\n      <li>Pryleugan (DE);</li>\n      <li>Sermonil (TH);</li>\n      <li>Talpramin (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Tofranil (AE, AR, AT, AU, BB, BD, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CO, CY, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, ID, IE, IL, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PH, PK, PL, PT, PY, QA, RU, SA, SC, SD, SE, SK, SL, SN, SR, SY, TN, TR, TT, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);</li>\n      <li>Tofranil-PM (AR, PY);</li>\n      <li>Tofyram (JO);</li>\n      <li>Tolerade (AU);</li>\n      <li>Topramine (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. <i>Obstet Gynecol</i>. 2008;111(4):1001-1020.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/18378767/pubmed\" target=\"_blank\" id=\"18378767\">18378767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Agras.1987\"></a>Agras WS, Dorian B, Kirkley BG. Imipramine in the treatment of bulimia: A double-blind controlled study. <i>Intl J of Eating Disorders</i>. 1987;6(1):29-38.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Altshuler LL, Hendrick VC. Pregnancy and psychotropic medication: changes in blood levels. <i>J Clin Psychopharmacol</i>. 1996;16(1):78-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/8834425/pubmed\" target=\"_blank\" id=\"8834425\">8834425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement. Clinical Practice Guidelines: Treatment of the School-Aged Child With Attention-Deficit/Hyperactivity Disorder,&rdquo; <i>Pediatrics</i>, 2001, 108(4):1033-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/11581465/pubmed\" target=\"_blank\" id=\"11581465\">11581465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Psychiatric Association (APA). Treatment recommendations for patients with major depressive disorder. 3rd ed. May 2010. Available at http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. 2009. Available at: http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Psychiatric Association. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. 2004. Available at:http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/acutestressdisorderptsd.pdf/u003c/div/u003e/r/n/u003c/li/u003e/r/n/u003cli/u003e/r/n/u003cdiv class/u003d\"reference\">\n    \n      <a name=\"22540422\"></a>Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, M&ouml;ller HJ; WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care [Published corrections appear in: <i>Int J Psychiatry Clin Pract</i>. 2012;16(3):242. <i>Int J Psychiatry Clin Pract</i>. 2013;17(1):76.]. <i>Int J Psychiatry Clin Pract</i>. 2012;16(2):77-84. doi: 10.3109/13651501.2012.667114.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/22540422/pubmed\" target=\"_blank\" id=\"22540422\">22540422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10815116\"></a>Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial [published corrections appear in <i>JAMA</i>. 2000;284(19):2450 and <i>JAMA</i>. 2001;284(20):2597.]. <i>JAMA</i>. 2000;283(19):2529-2536.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/10815116/pubmed\" target=\"_blank\" id=\"10815116\">10815116</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer M, Whybrow PC, Anst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and substhreshold depressions. <i>World Journal of Biological Psychiatry</i>. 2002;3(2):69-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/12479080/pubmed\" target=\"_blank\" id=\"12479080\">12479080</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benedek DM, Friedman MJ, Zatzick D, et al, &ldquo;Guideline Watch (March 2009): Practice Guideline for the Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder.&rdquo; Available at http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/acutestressdisorderptsd-watch.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Birmaher B, Brent D, AACAP Work Group on Quality Issues, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(11):1503-1526.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/18049300/pubmed\" target=\"_blank\" id=\"18049300\">18049300</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boyer WF, Friedel, RO. Antidepressant and antipsychotic plasma levels. <i>Psychiatric Clinics of North America</i>. 1984;7(3):601-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/6148744/pubmed\" target=\"_blank\" id=\"6148744\">6148744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bril V, England J, Franklin GM, et al, &quot;Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation,&quot; <i>Neurology</i>, 2011, 76(20):1758-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/21482920/pubmed\" target=\"_blank\" id=\"21482920\">21482920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1540759\"></a>Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators. <i>J Psychiatr Res</i>. 1993;27 Suppl 1:127-142.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/1540759/pubmed\" target=\"_blank\" id=\"1540759\">1540759</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dopheide JA. Recognizing and treating depression in children and adolescents. <i>Am J Health Syst Pharm</i>. 2006;63(3):233-243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/16434782 /pubmed\" target=\"_blank\" id=\"16434782 \">16434782 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17920770\"></a>Dworkin RH, O&rsquo;Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. <i>Pain</i>. 2007;132:237-251.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/17920770/pubmed\" target=\"_blank\" id=\"17920770\">17920770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fava M. Prospective studies of adverse events related to antidepressant discontinuation. <i>Journal of Clinical Psychiatry</i>. 2006; 67(Suppl 4):14-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/16683858/pubmed\" target=\"_blank\" id=\"16683858\">16683858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fortinguerra F, Clavenna A, and Bonati M, &quot;Psychotropic Drug Use During Breastfeeding: A Review of the Evidence,&quot; <i>Pediatrics</i>, 2009, 124(4):e547-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/19736267/pubmed\" target=\"_blank\" id=\"19736267\">19736267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3048121\"></a>Frank JB, Kosten TR, Giller EL, Dan E. A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. <i>Americal Journal of Psychiatry</i>. 1988;145(10):1289-1291.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/3048121/pubmed\" target=\"_blank\" id=\"3048121\">3048121</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedlander AH and Mahler ME, &ldquo;Major Depressive Disorder. Psychopathology, Medical Management, and Dental Implications,&rdquo; <i>J Am Dent Assoc</i>, 2001, 132(5):629-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/11367967 /pubmed\" target=\"_blank\" id=\"11367967 \">11367967 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ganzberg S, &ldquo;Psychoactive Drugs,&rdquo; <i>ADA Guide to Dental Therapeutics</i>, 2nd ed, Chicago, IL: ADA Publishing, a Division of ADA Business Enterprises, Inc, 2000, 376-405.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3043370\"></a>Gualtieri CT, Evans RW. Motor performance in hyperactive children treated with imipramine. <i>Perceptual and Motor Skills. </i>1988;66:763-769. doi: 10.2466/pms.1988.66.3.763.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/3043370/pubmed\" target=\"_blank\" id=\"3043370\">3043370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haddad PM. Antidepressant discontinuation syndromes. <i>Drug Safety</i>. 2001;24(3):183-197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/11347722/pubmed\" target=\"_blank\" id=\"11347722\">11347722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Himpel S, Banaschewski T, Heise CA, et al. The Safety of Non-stimulant Agents for the Treatment of Attention-Deficit Hyperactivity Disorder. <i>Expert Opin Drug Saf</i>. 2005;4(2):311-321.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/15794722/pubmed\" target=\"_blank\" id=\"15794722\">15794722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imipramine pamoate capsules [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp: August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25081580\"></a>Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. <i>BMC Psychiatry. </i>2014;14(Suppl 1): S1. doi: 10.1186/1471-244X-14-S1-S1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/25081580/pubmed\" target=\"_blank\" id=\"25081580\">25081580</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2051152\"></a>Kosten TR, Frank JB, Dan E, et al. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. <i>Journal of Nervous and Mental Disease</i>. 1991; 179(6):366-370.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/2051152/pubmed\" target=\"_blank\" id=\"2051152\">2051152</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6366276\"></a>Kvinesdal B, Molin J, Froland A, Gram LF. Imipramine treatment of painful diabetic neuropathy. <i>JAMA</i>. 1984;251(13):1727-1730.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/6366276/pubmed\" target=\"_blank\" id=\"6366276\">6366276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12884888\"></a>Mavissakalian MR, Perel JM. Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. <i>Arch Gen Psychiatry</i>. 1999;56(9):821-827.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/12884888/pubmed\" target=\"_blank\" id=\"12884888\">12884888</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2405806\"></a>Mitchell JE, Pyle RL, Eckert ED, et al. A comparison study of antidepressants and structured intensive group psychotherapy in the treatment of bulimia nervosa. <i>Arch Gen Psychiatry</i>. 1990;47(2):149-157<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/2405806/pubmed\" target=\"_blank\" id=\"2405806\">2405806</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Collaborating Centre for Mental Health (NCCMH). Depression: The NICE guideline on the treatment and management of depression in adults (updated edition). National Institute for Health &amp; Clinical Excellence (NICE). 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"NICE.2009\"></a>National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson JC and Devanand DP, &quot;A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,&quot; <i>J Am Geriatr Soc</i>, 2011;59(4):577-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/21453380/pubmed\" target=\"_blank\" id=\"21453380\">21453380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orsulak PJ, Schildkraut JJ. Guidelines for therapeutic monitoring of tricylic antidepressant plasma levels. <i>Thera Drug Monit</i>. 1979;1(2): 199-208.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/555572/pubmed\" target=\"_blank\" id=\"555572\">555572</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pass SE, Simpson RW. Discontinuation and reinstitution of medications during the perioperative period. <i>Am J Health Syst Pharm</i>. 2004;61(9):899-912.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/15156966/pubmed\" target=\"_blank\" id=\"15156966\">15156966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perrin JM, Friedman RA, Knilans TK; Black Box Working Group; Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. <i>Pediatrics</i>. 2008;122(2):451-453.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/18676566/pubmed\" target=\"_blank\" id=\"18676566\">18676566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pharmacy Quality Alliance. Use of high-risk medications in the elderly (HRM). http://pqaalliance.org/images/uploads/files/HRM2015.pdf. Published 2015. Accessed October 26, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pliszka S and AACAP Work Group on Quality Issues. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(7):894-921.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/17581453/pubmed\" target=\"_blank\" id=\"17581453\">17581453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6342421\"></a>Pope HG Jr, Hudson JI, Jonas JM, Yurgelun-Todd D. Bulimia treated with imipramine: a placebo-controlled, double-blind study. <i>Am J Psychiatry</i>. 1983;140(5):554-558<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/6342421/pubmed\" target=\"_blank\" id=\"6342421\">6342421</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rabenda V, Nicolet D, Beaudart C, et al. Relationship between use of antidepressants and risk of fractures: a meta-analysis. <i>Osteoporos Int</i>. 2013;24(1):121-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/22638709/pubmed\" target=\"_blank\" id=\"22638709\">22638709</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"4598851\"></a>Rapoport JL, Quinn PO, Bradbard G, et al. Imipramine and methylphenidate treatments of hyperactive boys. <i>Arch Gen Psychiatry.</i> 1974;30(6):789-793.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/4598851/pubmed\" target=\"_blank\" id=\"4598851\">4598851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. <i>Bone</i>. 2012;51(3):606-613.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/22659406/pubmed\" target=\"_blank\" id=\"22659406\">22659406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sallee FR, Pollock BG. Clinical pharmacokinetics of imipramine and desipramine. <i>Clin Pharm</i>. 1990;18(5):346-364.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/2185906/pubmed\" target=\"_blank\" id=\"2185906\">2185906</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. <i>Journal of Clinical Psychiatry</i>. 2006;67(Suppl 4):27-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/16683860/pubmed\" target=\"_blank\" id=\"16683860\">16683860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelton, RC. Steps following attainment of remission: discontinuation of therapy. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(4):168-174.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/15014601/pubmed\" target=\"_blank\" id=\"15014601\">15014601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12707430\"></a>Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. <i>Neurology</i>. 2003;60(8):1284-1289.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/12707430/pubmed\" target=\"_blank\" id=\"12707430\">12707430</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2792168\"></a>Sindrup SH, Ejlertsen B, Froland A, et al. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. <i>Eur J Clin Pharmacol</i>. 1998;37(2):151-153.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/2792168/pubmed\" target=\"_blank\" id=\"2792168\">2792168</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2147235\"></a>Sindrup SH, Gram LF, Brosen K, et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. <i>Pain</i>. 1990a;42(2):135-144.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/2147235/pubmed\" target=\"_blank\" id=\"2147235\">2147235</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sovner R and Orsulak PJ, &quot;Excretion of Imipramine and Desipramine in Human Breast Milk,&quot; <i>Am J Psychiatry</i>, 1979, 136(4A):451-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/426114/pubmed\" target=\"_blank\" id=\"426114\">426114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Task Force on the Use of Laboratory Tests in Psychiatry. Tricyclic antidepressants&mdash;blood level measurements and clinical outcome: an APA Task Force report. Task Force of the Use of Laboratory Tests in Psychiatry. <i>Am J of Psychiatry</i>. 1985;142(2):155-162.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/3881999/pubmed\" target=\"_blank\" id=\"3881999\">3881999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tofranil (imipramine) [prescribing information]. Hazelwood, MO: Mallinckrodt Inc; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tofranil-PM (imipramine) [prescribing information]. Hazelwood, MO: Mallinckrodt Inc; June 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15617511\"></a>Ursano RJ, Bell C, Eth S, et al. Work Group on ASD and PTSD, Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. <i>Am J of Psychiatry</i>. 2004;161(11 Suppl):3-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/15617511/pubmed\" target=\"_blank\" id=\"15617511\">15617511</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vetter VL, Elia J, Erickson CH, et al. Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder:. A Scientific Statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. <i>Circulation</i>. 2008;117(18):2407-2423.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/18427125/pubmed\" target=\"_blank\" id=\"18427125\">18427125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner KD. Pharmacotherapy for major depression in children and adolescents. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2005;29(5):819-826.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/15908090/pubmed\" target=\"_blank\" id=\"15908090\">15908090</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warner, CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. <i>Am Fam Physician</i>. 2006;74:449-456.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/16913164/pubmed\" target=\"_blank\" id=\"16913164\">16913164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yagiela JA, &ldquo;Adverse Drug Interactions in Dental Practice: Interactions Associated With Vasoconstrictors. Part V of a Series,&rdquo; <i>J Am Dent Assoc</i>, 1999, 130(5):701-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/10332135 /pubmed\" target=\"_blank\" id=\"10332135 \">10332135 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. <i>Obstet Gynecol</i>. 2009;114(3):703-713.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/19701065/pubmed\" target=\"_blank\" id=\"19701065\">19701065</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoshida K, Smith B, Craggs M, et al. Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. <i>J Affect Disord</i>. 1997;43(3):225-237.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipramine-drug-information/abstract-text/9186793/pubmed\" target=\"_blank\" id=\"9186793\">9186793</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8554 Version 228.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708918\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F182136\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F182137\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F182180\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F182141\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F182158\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F182142\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15897618\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15897619\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F182116\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F182101\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F23797397\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874618\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F182120\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474698\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F182188\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F182108\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F182123\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F182105\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F182174\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F182110\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10949669\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F10949670\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F182113\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F182117\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F182104\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F182122\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F182125\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F182126\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8554|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=imipramine-patient-drug-information\" class=\"drug drug_patient\">Imipramine: Patient drug information</a></li><li><a href=\"topic.htm?path=imipramine-pediatric-drug-information\" class=\"drug drug_pediatric\">Imipramine: Pediatric drug information</a></li></ul></div></div>","javascript":null}